Veness Adam M 4

What Happened

• Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics (DNTH), exercised stock options to acquire 30,000 shares on 2026-06-17 at $17.88 per share for a cost of $536,400. On the same day he sold a total of 30,000 shares in two open-market transactions, receiving aggregate proceeds of approximately $2,423,958.
• Sales details: 16,771 shares disposed at a weighted average price of $80.34 (range $80.00–$80.99) for $1,347,382, and 13,229 shares disposed at a weighted average price of $81.38 (range $81.00–$81.80) for $1,076,576. The filing also shows a separate derivative disposition of 30,000 shares at $0.00 (reported as a derivative transaction).

Key Details

• Transaction date: 2026-06-17; Form 4 filed 2026-06-18 (timely filing).
• Options exercised: 30,000 shares @ $17.88 (total cash paid $536,400).
• Shares sold: 30,000 total (16,771 and 13,229) for about $2.42M combined (weighted-average prices reported; see footnotes for price ranges).
• Notable footnotes: Sales were effected under a Rule 10b5-1 trading plan adopted March 18, 2026. The reported sale prices are weighted averages across multiple executions (ranges provided in the filing). Vesting schedule note: related option award vests monthly over four years from Jan 1, 2024.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

• This filing shows an option exercise paired with same-day open-market sales. That pattern can reflect a planned exercise-and-sell (or settlement/withholding) rather than an ongoing trading decision; here the sales were executed under a pre-established 10b5-1 plan.
• The separate derivative disposition reported at $0.00 may reflect internal option/settlement mechanics reported on the Form 4; the filing does not explain motivations. All facts above are from the Form 4 filings and accompanying footnotes.